EP 2254862 A2 20101201 - AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME
Title (en)
AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME
Title (de)
VON AZETIDIN ABGELEITETE VERBINDUNGEN, VERFAHREN ZU DEREN HERSTELLUNG UND DEREN THERAPEUTISCHE VERWENDUNG
Title (fr)
COMPOSÉS DÉRIVÉS D'AZÉTIDINES, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE
Publication
Application
Priority
- FR 2009000214 W 20090227
- FR 0801117 A 20080229
Abstract (en)
[origin: TW200940503A] Compounds corresponding to the formula (I) in which: R represents a (C1-C6)alkyl group or a halo(C1-C6)alkyl group; R1 represents a hydrogen atom or a (C1-C6)alkyl group; R2 represents a (C1-C6)alkyl group substituted by one or more groups chosen from the hydroxyl group, the (C1-C6)alkoxy group and optionally substituted by a halo(C1-C6)alkyl group; heterocycle group optionally substituted by one or more hydroxyls, a (C1-C6)alkoxy group or a hydroxy(C1-C6)alkyl group; heterocycle(C1-C6)alkyl group optionally substituted by one or more hydroxyls; R3 and R4 each represent a phenyl group, optionally substituted by one or more atoms or groups chosen from a hydrogen atom, a halogen, a (C1-C6)alkyl group, a halo(C1-C6)alkyl group, a (C1-C6)alkoxy group, a halo(C1-C6)alkoxy group or cyano; Y represents hydrogen atom, a halogen, a (C1-C6)alkyl group, a halo(C1-C6)alkyl group, a (C1-C6)alkoxy group, a halo(C1-C6)alkoxy group, a (C1-C6)alkylS(O)p group or cyano; p is between 0 and 2; in the form of the base or of an addition salt with an acid. Process of preparation and therapeutic application.
IPC 8 full level
C07D 205/04 (2006.01); A61K 31/40 (2006.01); A61P 3/10 (2006.01); A61P 25/28 (2006.01); A61P 35/00 (2006.01); C07D 405/12 (2006.01)
CPC (source: EP US)
A61P 1/00 (2017.12 - EP); A61P 1/04 (2017.12 - EP); A61P 1/08 (2017.12 - EP); A61P 1/12 (2017.12 - EP); A61P 1/16 (2017.12 - EP); A61P 3/00 (2017.12 - EP); A61P 3/04 (2017.12 - EP); A61P 3/06 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 5/00 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 11/16 (2017.12 - EP); A61P 13/00 (2017.12 - EP); A61P 13/10 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 19/10 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/02 (2017.12 - EP); A61P 25/04 (2017.12 - EP); A61P 25/16 (2017.12 - EP); A61P 25/18 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 25/30 (2017.12 - EP); A61P 25/34 (2017.12 - EP); A61P 27/06 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 31/00 (2017.12 - EP); A61P 31/12 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 37/02 (2017.12 - EP); C07D 205/04 (2013.01 - EP US); C07D 405/12 (2013.01 - EP US)
Citation (search report)
See references of WO 2009118473A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA RS
DOCDB simple family (publication)
FR 2928149 A1 20090904; FR 2928149 B1 20110114; AR 070485 A1 20100407; AU 2009229026 A1 20091001; BR PI0908336 A2 20150804; CA 2716961 A1 20091001; CL 2009000464 A1 20100409; CN 101959855 A 20110126; CO 6251235 A2 20110221; EA 201071012 A1 20110429; EP 2254862 A2 20101201; IL 207799 A0 20101230; JP 2011513285 A 20110428; KR 20100122489 A 20101122; MA 32192 B1 20110401; MX 2010009512 A 20101215; PE 20091431 A1 20091019; TW 200940503 A 20091001; US 2011053908 A1 20110303; UY 31682 A1 20090930; WO 2009118473 A2 20091001; WO 2009118473 A3 20091119
DOCDB simple family (application)
FR 0801117 A 20080229; AR P090100656 A 20090226; AU 2009229026 A 20090227; BR PI0908336 A 20090227; CA 2716961 A 20090227; CL 2009000464 A 20090227; CN 200980106991 A 20090227; CO 10102306 A 20100819; EA 201071012 A 20090227; EP 09724410 A 20090227; FR 2009000214 W 20090227; IL 20779910 A 20100825; JP 2010548143 A 20090227; KR 20107019131 A 20090227; MA 33175 A 20100913; MX 2010009512 A 20090227; PE 2009000286 A 20090226; TW 98106237 A 20090226; US 86928110 A 20100826; UY 31682 A 20090227